Belite Bio, Inc Belite Bio, Inc

Belite Bio, Inc

BLTE

Ранг среди акций #3145
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Цена акции
$143.80
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$5.74B
Изменение (1 день)
-5.78%
Изменение (1 год)
63.95%
Страна
US
Торговля Belite Bio, Inc (BLTE)

Категория

Healthcare
EPS для Belite Bio, Inc (BLTE)
EPS по состоянию на June 2026 TTM: $-2.76
Согласно последним финансовым отчетам и цене акций Belite Bio, Inc, текущий EPS компании (TTM) составляет $-2.76. В конце 2023 EPS компании составлял $-1.19, больше, чем показателю 2022 года, равному $-0.63.
История EPS компании Belite Bio, Inc с 2020 по 2026
EPS на конец каждого года
Год EPS Изменить
2026 (TTM) $-2.76 133.90%
2024 $-1.18 -0.84%
2023 $-1.19 88.89%
2022 $-0.63 57.50%
2021 $-0.40 -35.48%
2020 $-0.62 0.00%
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -727.54%
US
$-7.98 189.13%
US
$-5.29 91.67%
AU
- -
CH
$27.74 -1,105.07%
NL